BioCryst Pharmaceuticals (BCRX) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xeris Biopharma (XERS) has outperformed BioCryst Pharmaceuticals (BCRX) over the past year, gaining 24.3% versus a gain of 13.9%. Over five years, XERS leads with a +409.5% price change compared with -45.2% for BCRX. BioCryst Pharmaceuticals is the larger company by market cap ($2.19 billion vs $1.91 billion), about 1.1 times the size.
On valuation, BioCryst Pharmaceuticals trades at a lower forward P/E (9.1x vs 28.3x for Xeris Biopharma). BioCryst Pharmaceuticals converts more of its revenue into profit, with a net margin of 30.2% versus 0.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCRX | XERS |
|---|---|---|
| Share price | $8.56 | $10.48 |
| Market cap | $2.19B | $1.91B |
| 1-day change | +3.20% | +2.84% |
| YTD return | +6.28% | +29.81% |
| 1-year return | +13.87% | +24.27% |
| 5-year return | -45.21% | +409.50% |
| Forward P/E | 9.10 | 28.32 |
| EPS (TTM) | $-1.40 | $-0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $874.84M | $291.85M |
| Revenue growth (YoY) | +94.10% | +43.72% |
| Net income (latest FY) | $263.86M | $554.00K |
| Gross margin | 97.82% | 85.41% |
| Operating margin | 38.98% | 8.53% |
| Net margin | 30.16% | 0.19% |
| 52-week high | $11.22 | $11.33 |
| 52-week low | $6.00 | $5.25 |
| Distance from 52-week high | -23.75% | -7.50% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +142.31% | +22.71% |
| Average volume | 4.13M | 2.17M |
| Shares outstanding | 255.54M | 182.32M |
| Employees | 435 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XERS has outperformed BCRX by 10.4 percentage points over the past year.
- BioCryst Pharmaceuticals is more profitable, keeping 30.2 cents of every revenue dollar as net income versus 0.2 cents for Xeris Biopharma.
- BioCryst Pharmaceuticals grew revenue faster in its latest fiscal year (+94.10% vs +43.72%).
About BioCryst Pharmaceuticals
BCRX stock →BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 435 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
BCRX vs XERS FAQ
Which is bigger, BioCryst Pharmaceuticals or Xeris Biopharma?
BioCryst Pharmaceuticals (BCRX) is larger, with a market capitalization of $2.19B compared with $1.91B for Xeris Biopharma (XERS).
Which stock has performed better over the past year, BCRX or XERS?
XERS returned +24.27% over the past 12 months, compared with +13.87% for BCRX (price return, excluding dividends). Past performance does not predict future results.
Are BioCryst Pharmaceuticals and Xeris Biopharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for BioCryst Pharmaceuticals and Biotechnology: Pharmaceutical Preparations for Xeris Biopharma.